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Abstract: Over one million fractures occur per year in the US and are associated with impaired 
healing increasing patient morbidity, stress, and economic costs. Despite improvements in 
surgical technique, internal ﬁ  xation, and understanding of biologics, fracture healing is delayed 
or impaired in up to 4% of all fractures. Complications due to impaired fracture healing present 
therapeutic challenges to the orthopedic surgeon and often lead to chronic functional and 
psychological disability for the patient. As a result, it has become clinically desirable to augment 
mechanical ﬁ  xation with biologic strategies in order to accelerate osteogenesis and promote 
successful arthrodesis. The discovery of bone morphogenic protein (BMP) has been pivotal in 
understanding the biology of fracture healing and has been a source of intense clinical research as 
an adjunct to fracture treatment. Multiple in vitro and in vivo studies in animals have elucidated 
the complex biologic interactions between BMPs and cellular receptors and have convincingly 
demonstrated rhBMP-2 to be a safe, effective treatment option to enhance bone healing. Multiple 
clinical trials in trauma surgery have provided level 1 evidence for the use of rhBMP-2 as a safe 
and effective treatment of fractures. Human clinical trials have provided further insight into 
BMP-2 dosage, time course, carriers, and efﬁ  cacy in fracture healing of tibial defects. These 
promising results have provided hope that a new biologic ﬁ  eld of technology has emerged as 
a useful adjunct in the treatment of skeletal injuries and conditions.
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Introduction
The devastating effects of fractures are felt every year in the US. Over one million 
fractures occur per year and are associated with impaired healing increasing patient 
morbidity, stress, and economic cost (Einhorn 1995, 1998). Despite improvements in 
surgical technique, internal ﬁ  xation and understanding of biologics, fracture healing 
is delayed or impaired in up to 4% of all fractures (Whittle et al 1992; Tornetta et al 
1994; Einhorn 1995; Heckman and Sarasohn-Kahn 1997; Marsh 1998; Karladani et al 
2000; Young and Rayan 2000). Factors affecting fracture healing include severity of 
injury, patient comorbidities, and surgical ﬁ  xation. Complications due to impaired 
fracture healing present therapeutic challenges to the orthopedic surgeon and often 
lead to chronic functional and psychological disability for the patient. As a result, it has 
become clinically desirable to augment mechanical ﬁ  xation with biologic strategies in 
order to accelerate osteogenesis and promote successful arthrodesis. The purposes of the 
following manuscript include: 1) to review the biology of bone morphogenic protein-2 
(BMP-2, Medtronic Sofamor Danek, Memphis, TN, USA); 2) to identify important 
animal data that support the use of BMP-2 in fracture treatment; 3) to present recently 
published human clinical data on the use of BMP-2 in orthopedic fracture care.
Fracture repair
Bone is a unique organ that continuously remodels and has the capability to regenerate 
throughout adult life (Cheng et al 2003). Fracture repair includes a complex interaction Biologics: Targets & Therapy 2008:2(3) 346
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between mechanical (fracture stability) and biological factors 
(growth factors/proteins). The physiological and biological 
factors responsible for the regeneration of bone are coupled 
to and dependent on BMPs.
Fracture of bone leads to a cascade of events including 
activation of the complement cascade and an inﬂ  ammatory 
response associated with vascular injury leading to cell 
extravasation and signaling (Gautschi et al 2007). Activated 
macrophages release growth factors that stimulate endothelial 
cells to express plasminogen activator and procollagenase 
(Schmitt et al 1999). Initiation of the clotting cascade by 
platelets allows the localized collection of blood to clot 
and form a hematoma. This hemostatic plug prevents 
further blood loss and provides a medium for the activity 
of various growth factors including platelet-derived growth 
factor (PDGF), transforming growth factor-beta (TGF-β), 
and beta-ﬁ  broblast growth factor (β-FGF) (Hollinger and 
Wong 1996).
Approximately 3 days after a fracture, a repair blas-
tema forms consisting of new blood vessels, macrophages, 
and collagen (Hollinger and Wong 1996). Growth factors 
selectively bind to collagen, forming a substrate to optimize 
interaction between TGF-β, β-FGF, PDGF, BMPs, and 
receptor cells (Figure 1). Osteoprogenitor cells localized 
to the periosteum and endosteum of fractured bone attach 
to granulation tissue and differentiate into chondrocytes 
and osteoblasts via cell signaling. The aggregate effects of 
cellular transduction and enhanced cellular-growth factor 
interaction help to regenerate bone via osteoblastic and osteo-
clastic activity and ensure fracture healing by 6–8 weeks after 
injury (Hollinger and Wong 1996). Degradation products 
from the extracellular matrix stimulate the differentiation of 
macrophages into osteoclasts in order to provide additional 
cells for continued fracture healing (Schmitt et al 1999).
The ﬁ  nal pathway in bone healing and regeneration 
depends on the interaction between BMP’s/growth factors 
with the various cell lines at the site of injury (Reddi 1994). 
Sufﬁ  cient quantities of biologically active BMPs and compe-
tent cells interact to regenerate bone (Schmitt et al 1999).
BMP biology
In 1965, Marshall R Urist discovered a substance in the 
extracellular bone matrix that had the ability to induce osteo-
genesis when implanted into extraskeletal tissue (Urist 1965). 
Ever since this seminal discovery of bone morphogenic 
proteins, the role of BMP has expanded from basic biology 
to clinical applications. In 1998, scientists at the Genetics 
Institute in Cambridge, MA, USA derived the amino acid 
sequence of BMPs. This discovery led to the expression of 
complementary DNAs and recognization of BMP in the 
family of the transforming growth factor-β supergene family 
(Einhorn 1998). Over the past 2 decades, 20 BMPs with 
varying abilities to induce cartilage or bone formation have 
been identiﬁ  ed by investigators (Gautschi et al 2007). The 
structure of 16 different human BMPs have been identiﬁ  ed 
and designated as BMP-1 to BMP-16. With the exception 
of BMP-1, the BMPs are a subgroup of the transforming 
growth factor-β superfamily which is a group of differentia-
tion factors that have been shown to play an integral role in 
tissue repair (Ozkaynak et al 1992; Barnes et al 1999, 2003; 
Termaat et al 2005).
Enhanced fracture healing relies on two processes: 
mechanical and biologic intervention (Linkhart et al 1996; 
Claes et al 1998; Bostrom et al 1999). Biological agents 
recapitulate the process of both embryological bone forma-
tion and fracture healing; thus these agents have the potential 
to be used clinically in their natural setting (Marsh 1998). 
Among the numerous cytokines and growth factors such as 
BMPs, TGF-β, FGF-1 (ﬁ  broblast growth factor), and IGF-1 
(insulin like growth factor) involved in fracture healing, 
BMPs are regarded as the key regulators in the cascade of 
events required for skeletal repair (Onishi et al 1998; Sakou 
1998; Wozney and Rosen 1998).
In the ﬁ  rst 5 days after a fracture, a cascade of events inte-
gral to fracture healing occurs. Progenitor cells indigenous 
to the fracture site are recruited through cell signaling via 
BMPs. The interaction of BMP-2 with these osteoprogenitor 
cells leads to induction of bone-forming osteoblasts. This 
marks a sentinel event for bone regeneration. BMPs bind 
BONE
WOUND
Platelets
TGF-β
Chemotaxis
Proliferation
Chemotaxis
Proliferation
Progenitor cells
PDGF
Differentiation BMPs
Chondrocytes Osteoblasts
BMPs released from
bone matrix
VEGF
PDGF
BMPs Progenitor cells
Angiogenesis
BMP
Figure 1 Cell signaling in chemotaxis and cell proliferation during wound-healing: Platelet 
derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transform-
ing growth factor-beta (TGF-β) play an integral role in the signal cascade responsible for 
chemotaxis and cell migration during wound-healing. The recruitment of osteoprogenitor 
cells and their proliferation provides a pool of cells that will respond to bone morphogenic 
protein (BMP). Reproduced with permission from Hollinger JO, et al 2008. Recombinant 
human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg 
Am, 90:48–54. Copyright © 2008. The Journal of Bone and Joint Surgery, Inc.Biologics: Targets & Therapy 2008:2(3) 347
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and initiate a cell signal through a transmembrane receptor 
complex formed by type I and II serine/threonine kinase 
receptor proteins. Type II receptors are active continuously 
and function upstream of the type I receptors but cannot 
independently initiate cell signaling (Wrana et al 1994). After 
binding BMP-2, the type II receptor kinase phosphorylates 
the type I receptor, generating an intracellular response.
Studies have shown that BMP-2 through 7 and BMP-9 
have the unique ability to induce differentiation of 
mesenchymal stem cells into osteoblasts (Chen et al 1991; 
Yamaguchi et al 1991; Hughes et al 1995; Mayer et al 1996). 
BMP-2, 6, and 9 play an important role in the early phase 
of differentiation of mesenchymal progenitor cells to pre-
osteoblasts. In mesenchymal progenitor and osteoblastic 
cells, Cheng et al demonstrated the relative osteoconductivity 
of different BMPs at various stages in the differentiation 
process. Speciﬁ  cally, BMP-2, 6, and 9 were shown to play 
a pivotal role in the early phase of the differentiation of 
mesenchymal progenitor cells to pre-osteoblasts. These 
findings could implicate BMP-2, 6, and 9 as essential 
effectors in fracture healing where there is an abundance of 
pluripotent cells and pre-osteoblasts.
Although many BMP subtypes have been shown to have 
osteoinductive properties, only rhBMP-2 and rhBMP-7 have 
been developed and used for clinical applications (Cheng 
et al 2003). Multiple animal models have demonstrated that 
fracture healing can be accelerated by local administration 
of rhBMP-2 (Ozkaynak et al 1992; Bostrom et al 1999; den 
Boer et al 2002). BMP-2 plays an important role in the early 
phase of differentiation of mesenchymal progenitor cells to 
pre-osteoblasts.
Tsuji et al (2006) evaluated the role of BMP-2 in fracture 
healing by creating transgenic mice lacking limb speciﬁ  c 
expression of BMP-2. These mice did not have defects in 
skeletal patterns but did develop dose-dependent defects in 
bone mineral density. Femoral fractures in these mice showed 
failure to heal by day 20 compared with heterozygotes and 
control groups. Mice lacking BMP-2 had delayed activation 
of the periosteum in response to the fracture in addition 
to the absence of callus formation and mesenchymal 
progenitor cells.
In vitro BMP-2 analysis
The functions of BMPs have been evaluated in many cell lines 
including osteoprogenitor cells, osteoblasts, and chondroblasts. 
In a study using C3H10T1/2 cells (mouse mesodermal progenitor 
cells), Wang et al (1993) demonstrated that high concentrations 
of BMP-2 induced differentiation into chondrocytes and bone 
cells. Other studies have implicated BMP-2 in the conversion 
of rat calvaria derived multipotent cells (ROB-C26) and clonal 
myoblast cells (C2C12) into cells of the osteoblast phenotype 
(Yamaguchi et al 1991; Katagiri et al 1994). Kanatani et al 
(1995) showed that BMP-2 stimulated bone resorption through 
direct stimulation of osteoclast formation and activation of 
mature osteoclasts in stromal cells of mouse bone cell cultures. 
Cheng et al (2003) used osteoblastic progenitor cell lines to 
demonstrate that BMP-2 was able to induce both early and late 
osteogenic markers and matrix mineralization. These studies 
provide compelling evidence for the role of BMP-2 in the 
biology of bone regeneration, leading to further interest and 
study in animal models.
Lower order animal trials
In several preclinical studies, a single percutaneous injec-
tion of recombinant human BMP-2 (rhBMP-2) in a calcium 
phosphate paste (alpha bone substitute material [α-BSM] 
accelerated osteotomy site healing in rabbit ulnar, canine 
tibial, and primate ﬁ  bular osteotomy models (Finkemeier 
2002; Khan et al 2005). In a study by Seeherman et al 
(2006a), a single percutaneous administration of 1.5 mg/mL 
rh BMP-2/calcium phosphate matrix increased primate ﬁ  bular 
osteotomy site callus area and accelerated radiographic 
evidence of healing up to 2 weeks after injury (Figure 2). 
In this study, a 1-week delay in rhBMP-2 treatment led 
to accelerated healing through direct bone formation. The 
authors noted that treatment with rhBMP-2 led to an increase 
in the number of Cbfa-1 positive cells in the osteotomy site. 
Cbfa-1 is a transcription factor that works with Osterix (OSX) 
to regulate osteoblast speciﬁ  c genes required for osteoblast 
differentiation and bone formation. These ﬁ  ndings correlate 
with in vitro studies that demonstrate that rhBMP-2 upregu-
lates expression of both Cbfa-1 and OSX (Wozney and Rosen 
1998; Kawaguchi et al 2001; Kolbeck et al 2003). On the 
basis of these results, Seeherman et al (2006a) concluded 
that an injectable form of rhBMP-2/-BSM can potentially be 
administered at any time up to 2 weeks after fracture injury 
accelerating the healing of closed fractures in humans.
Bouxsein et al (2001) studied the effect of rhBMP-2 in 
fracture healing in a rabbit ulnar osteotomy model. Seventy-
two rabbits had mid-ulnar osteotomies and were divided into 
3 treatment groups: 1) rhBMP-2/absorbable collagen sponge 
(ACS), 2) absorbable collagen sponge, 3) placebo. The reten-
tion of rhBMP-2 at the osteotomy site was determined with 
imaging of 125I-labeled rhBMP-2. The data revealed that oste-
otomy sites treated with rhBMP-2 healed 33% faster than the 
other two groups. At each time point analyzed (3, 4, 6 weeks), Biologics: Targets & Therapy 2008:2(3) 348
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Figure 2 Postoperative radiographic appearance of the nonhuman primate ﬁ  bular osteotomy sites that were untreated, treated with calcium phosphate matrix (CPM), and 
treated with 0.5, 1.5, and 4.5 mg/mL rhBMP-2/CPM administered 1 week after surgery. Reproduced with permission from Seeherman H, et al 2006a. rhBMP-2/calcium phosphate 
matrix accelerates osteotomy-site healing in a nonhuman primate model at multiple treatment times and concentrations. J Bone Joint Surg Am, 88:144–60. Copyright © 2006. 
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enhanced healing in the rhBMP-2 treated group appeared to 
be more rapid with greater callus formation and advanced 
callus maturation. The authors concluded that the presence 
of larger and more mature callus in the rhBMP-2 treatment 
group was consistent with the increased biomechanical 
properties of the ulna treated with rhBMP-2.
Other animal studies have also shown enhanced fracture 
healing following rhBMP-2 treatment. Welch et al (1998), 
in a tibial fracture model in goats, found that limbs treated 
with rhBMP-2/ACS had increased callus formation, radio-
graphic healing parameters, and torsional stiffness at 3 and 6 
weeks post-treatment. Dynamic histomorphometric analysis 
revealed increased callus formation consistent with recruit-
ment of osteoprogenitor cells (Boden et al 1998). Luppen 
et al (2002) studied 49 rabbits that were injected with saline 
or prednisone prior to creating bilateral ulnar osteotomies. 
One osteotomy was treated with rhBMP-2/ACS, and the 
contralateral osteotomy served as a control (Luppen et al 
2002). Healing was assessed in these animals with com-
puted tomography, torsional biomechanics, and histology. 
Although prednisolone inhibited healing in the control 
group, rhBMP-2/ACS enhanced fracture healing in both 
prednisolone- and saline-treated groups.
In a rat femur fracture model, Lee et al (2002) created a 
2 cm defect that was ﬁ  lled with rhBMP-2/ACS allograft. The 
authors reported 75% new bone incorporation into allograft 
at 4 weeks and 100% at 8 weeks. Einhorn et al (2003) used 
a femur fracture model in 144 rats to determine the effects 
of a single percutaneous injection of rhBMP-2 on fracture 
healing. The three treatment groups included a control group, 
a buffer vehicle group, and a rhBMP-2/buffer group. Torsional 
biomechanical testing indicated that the stiffness of the 
rhBMP-2 treated group was twice that of the two other control 
groups at the 2-, 3-, and 4-week time points. At 4 weeks, the 
strength of the rhBMP-2 treated fractures was 77% greater 
than that of the other groups. By 4 weeks, remodeling of the 
hard callus and recorticalization were observed in the rhBMP-2 
treated fracture sites, whereas cartilage and/or soft tissue were 
still present in the control fracture sites.
Several studies have looked at the effects of rhBMP-2 
on fracture healing in canine fracture models. In a study of 
mid-diaphyseal femoral defects ﬁ  lled with rhBMP2-allograft 
in 21 dogs, Zabka et al (2001) noted more balanced allograft 
resorption and bone formation in the rhBMP-2 group com-
pared with the cancellous bone group and ACS groups. Pluhar 
et al (2001) studied augmentation of allograft with rhBMP-
2/ACS in a canine intercalary femoral defect. The authors 
found that rhBMP-2/ACS allograft had results equal to or 
greater than those of autogenous graft. RhBMP-2 graft also 
resulted in greater callus formation. In a study of 18 dogs with 
bilateral ulnar defects, Cook et al (2005) compared allograft 
augmentation with rhBMP-2 against BMP-7. RhBMP-2 
treated defects formed greater bone at early time periods, with 
this trend continuing throughout the study. At the 12-week 
interval, bridging bone formed in all rhBMP-2 treated and 
autograft treated groups compared with 4 of 6 BMP-7 treated 
defects. Mean torsional strength was measured at 78% of 
an intact ulna, whereas autograft showed 47% strength and 
BMP-7 showed 38% strength.
Although several studies have reported enhanced fracture 
healing in animals with rhBMP-2 delivered in a buffer, 
optimal bone formation requires a carrier (Blokhuis et al 
2001; Bouxein et al 2001; Seeherman 2001; Einhorn et al 
2003). Carriers optimize BMP concentration at the pivotal 
stages of fracture healing, allowing osteoprogenitor cells to 
migrate to the site of repair, proliferate and differentiate into 
osteoclasts and osteoblasts. Moreover, carriers provide an 
osteoconductive matrix allowing for better handling proper-
ties needed for injection or implantation (Seeherman 2001). 
Bone regeneration can be optimized in segmental defects 
through the use of BMP carriers providing compression 
resistance and appropriate elution (Seeherman 2001).
A variety of BMP-carrier combinations has been used 
in animal models to enhance bone formation in segmental 
defects (den Boer et al 2003). A potential problem with most 
BMP-carrier combinations is that a second open surgical 
procedure is necessary for delayed administration of BMP 
after initial surgery to augment the repair. Additionally, 
soft tissue injury may prevent adequate initial treatment and 
require another open procedure for BMP implantation. An 
injectable BMP-carrier combination may allow physicians 
to circumvent this potential limitation. Multiple animal 
studies have reported accelerated fracture healing with the 
use of rhBMP-2 in an injectable calcium phosphate cement 
carrier (Li et al 2003; Edwards et al 2004; Seeherman et al 
2006b; Swiontkowski et al 2006). Currently, clinical trials 
are evaluating the efﬁ  cacy of rhBMP-2-carrier combination 
in the treatment of closed fractures.
Using a novel adenoviral gene therapy technique, 
Lieberman et al (1999) used BMP-2 producing bone marrow 
cells to treat rats with femoral defects. The results of this 
group were compared with a group treated with rhBMP-2 and 
3 control groups including defects treated with demineral-
ized bone matrix, β-galactosidase transduced bone marrow 
cells, and untreated defects. At the 2-month time point, 22 
of 24 defects in the gene therapy group and all defects in Biologics: Targets & Therapy 2008:2(3) 350
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the rhBMP-2 group showed enhanced fracture healing. In 
contrast, 1 of 32 defects in the three control groups healed. 
Thus, Lieberman et al (1999) showed that gene therapy 
can potentially be used as a therapeutic delivery system for 
rhBMP-2 in a feasible, efﬁ  cacious manner. With a similar 
technique, Lieberman et al noted enhanced bone healing in 
hindlimbs of mice treated with helper-dependent adenoviral 
vector producing BMP-2 (Abe et al 2002).
Despite the potential use of viral vectors to express growth 
factors, questions remain regarding its potential for uncon-
trolled BMP synthesis and possible malignant cell induction. 
Multiple studies have questioned the impact of excess BMP-2 
production in patients with osteosarcoma. With high doses 
of BMP, there will be more bone formation and rapid osteo-
induction than desired (Valentin-Opran et al 2002). BMP-2 
and BMP-2 receptors are expressed in a variety normal and 
malignant cell types, including osteosarcoma. Guo et al (1999) 
reported expression of BMP-2 receptor mRNA was correlated 
with metastasis of osteosarcoma. However, no data have 
shown that BMPs induce malignant transformation of cells. 
Although some studies have suggested that BMP-2 may 
stimulate the proliferation of malignant cells (Kleeff et al 
1999; Langenfeld et al 2003), most studies have shown that 
BMP-2 inhibits or has no effect on the proliferation of malig-
nant cells (Soda et al 1998; Orui et al 2000; Kumagai et al 
2006). With these conﬂ  icting reports, rhBMP-2 should not 
be implanted at the site of resected tumor or in patients with 
active malignancy.
Clinical trials
Multiple clinical trials in trauma surgery have provided 
level 1 evidence for the use of rhBMP-2 as a safe and 
effective treatment of fractures. In a prospective randomized, 
controlled study, Jones et al (2004a, b) studied the efﬁ  cacy 
of rhBMP-2 (INFUSE bone graft; Medtronic Sofamor 
Danek, Memphis, TN, USA) on an absorbable collagen 
sponge combined with freeze-dried cancellous autograft for 
grafting of diaphyseal tibial defects. Thirty patients were 
randomly enrolled in one of two groups: 1) control group 
with autogenous iliac crest bone graft, 2) treatment group 
with cancellous allograft with rhBMP-2/ACS. Patients were 
followed for 12 months with treatment failures deﬁ  ned as the 
inability to heal by 12-month follow-up or the need for sec-
ondary intervention to induce fracture healing. Five patients 
in the control group were deemed treatment failures whereas 
2 of 15 patients in the rhBMP-2 group did not obtain a solid 
arthrodesis. Jones et al (2004a,  b) concluded that rhBMP-2 
with cancellous allograft had a similar rate of healing to that 
of autogenous bone graft without donor site complaints, with 
reduced blood loss, and with shortened surgery time.
In a landmark multicenter study by the BESTT study group 
(BMP-2 Evaluation in Surgery for Tibial Trauma), Govender 
et al (2002) reported the results of a prospective, randomized 
controlled, single-blind study to evaluate the safety and efﬁ  -
cacy of the use of rhBMP-2 to accelerate healing and decrease 
the need for secondary intervention in open tibial fractures. The 
450 patients evaluated in this study were randomized to one 
of three groups: 1) intramedullary nail ﬁ  xation and soft tissue 
management, 2) IM nail ﬁ  xation, soft tissue management, and 
0.75 mg/mL (6 mg) rhBMP-2/ACS implant, 3) IM nail ﬁ  xa-
tion, soft tissue management, and 0.75 mg/mL (6 mg) rhBMP-
2/ACS implant and 1.5 mg/mL (12 mg) of rhBMP-2/ACS. At 
the time of deﬁ  nitive wound closure, the rhBMP-2 was placed 
over the fracture. The severity of the open wound was graded 
according to the Gustilo-Anderson classiﬁ  cation and was used 
to stratify the randomization. Stratum A comprised Gustilo 
Anderson types I, II, IIIA whereas Stratum B comprised 
Gustilo-Anderson type IIIB open fractures.
Four-hundred and twenty-one (91%) of the patients were 
seen at 12-month followup. At every time point (10 weeks to 
12-month follow-up), the rhBMP-2 treated groups had a sig-
niﬁ  cantly greater percentage of patients who had successful 
healing without hardware failure or the need for secondary 
intervention to achieve union (Figure 3). Compared with the 
control group, patients treated with 1.5 mg/mL rhBMP-2 
had a 44% reduction in the risk of failure (p = 0.0005), 
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Figure 3 Rate of fracture healing. Determination of fracture-healing was based on 
treating surgeons’ clinical and radiographic assessment. SOC = standard of care control 
group with IM nail ﬁ  xation and soft-tissue management, rhBMP-2/ACS = groups treated 
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signiﬁ  cantly fewer invasive interventions (p = 0.0264) such 
as bone-grafting and nail exchange, and signiﬁ  cantly faster 
fracture healing (p = 0.0022). Moreover, signiﬁ  cantly more 
patients treated with 1.5 mg/mL rhBMP-2 had healing at 
the fracture site at postoperative visits from 10 weeks to 
12 months (p = 0.008). At 6 months, the healing rate observed 
in the 1.5 mg/mL rhBMP-2 group was 21% higher than that 
in the control group. Compared with control patients, those 
treated with 1.5 mg/mL of rhBMP-2 also had signiﬁ  cantly 
fewer hardware failures (p = 0.0174), fewer infections 
(in association with Gustilo-Anderson type III injuries; 
p = 0.0219), and faster wound-healing (83% compared with 
65% had wound healing at 6 weeks; p = 0.001).
The results of this study demonstrate that patients with 
Gustilo type IIIA or IIIB fracture who had been treated with 
1.5 mg/mL rhBMP-2 implant had a signiﬁ  cantly reduced rate 
of infection compared with the control. The authors speculated 
that this effect was likely due to earlier achievement of fracture 
stability. The authors also noticed accelerated soft tissue heal-
ing and reduction in pain in patients treated with rhBMP-2. 
This potential reduction in pain may be related to an increased 
vascular supply that has been observed experimentally in 
rhBMP-2 induced bone formation. The authors also noted 
that infection rates were higher in this study compared to other 
reports as their deﬁ  nition of infection was conservative and 
included both superﬁ  cial and deep wounds. The data from this 
study led to the EMEA (European Agency for the Evaluation 
of Medicinal Products) approval of rhBMP-2/ACS in 2002 and 
FDA approval in 2004 for open tibial fractures treated with an 
IM nail (McKay et al 2007). An economic model based on the 
results of the BESTT study trial revealed cost savings to the 
payer when rhBMP-2 was reserved for patients with Gustilo 
type IIIA or IIIB fractures (Jones et al 2004b).
Between 1996 and 1999, two concurrent prospective, 
randomized controlled multicenter trials were performed to 
evaluate the efﬁ  cacy of rhBMP-2 in the treatment of open 
tibial fractures. Along with the BESTT trial which was subse-
quently published, a second unpublished study was conducted 
with the same study design and protocol for 60 patients at 
10 level-1 trauma centers in the US (Swiontkowski et al 
2006). Since many surgeons were unaware of this smaller 
study which showed that the rate of secondary intervention 
was reduced with the addition of rhBMP-2 to reamed or 
unreamed IM nailing, Swiontkowski et al (2006) reported 
a subgroup analysis of the combined results of these two 
studies. With a total of 520 patients from 59 trauma centers, 
Swiontowski et al analyzed two subgroups: 1) 131 patients 
with a Gustilo-Anderson type IIIA or IIIB open tibial 
fractures, 2) 113 patients treated with reamed intramedullary 
nailing. The ﬁ  rst subgroup demonstrated signiﬁ  cant improve-
ments with treatment of 1.5 mg/mL rhBMP-2 with fewer 
bone grafting procedures (p = 0.0005), decreased need for 
secondary invasive intervention (p = 0.0065), and a lower rate 
of infection (p = 0.0234) compared with the control group 
(Table 1). Analysis of subgroup II revealed that fractures 
treated with reamed IM nailing had no signiﬁ  cant difference 
between the control and rhBMP-2 groups (Table 2) In this 
study, Swiontowksi et al (2006) noted that patients in the 
rhBMP-2 group were bearing weight an average of 32 days 
sooner than the controls. The authors of this study concluded 
that rhBMP-2 can be used safely and acutely in patients who 
present with open tibial fractures with a plan that includes 
IM nailing and no staged bone-grafting.
Between 2000 and 2003, Jones et al (2006) performed 
a multicenter randomized controlled trial in 30 patients to 
investigate the beneﬁ  t of rhBMP-2 with allograft compared 
to autogenous bone graft for reconstruction of diaphyseal 
tibial fractures with cortical defects. Patients included in this 
study had residual fracture defect consistent with clinical 
recommendation for staged reconstruction with bone grafting 
(ie, a cortical defect measuring 1–5 cm in length and involving 
at least 50% of the circumference of the diaphysis) (Watson 
et al 1995; Whittle et al 1995; Templeman et al 1998); and had 
to have had initial treatment with either intramedullary nail 
or external ﬁ  xation. All 30 patients were enrolled 6–12 weeks 
after initial injury. Patients allocated to the allograft group 
received 1.5 mg/mL rhBMP-2/ACS as an onlay graft. Clinical 
evaluation of fracture healing included pain assessment 
with full weight bearing and fracture-site tenderness. The 
Short Musculoskeletal Function Assessment (SMFA) was 
administered before and after treatment with radiographs 
used to document union, the presence of bridging callus, and 
incorporation of bone-graft material.
Ten patients in the autograft group (66%) and 13 
patients (86%) in the rhBMP-2/allograft group had healing 
without further intervention. The mean estimated blood 
loss was 67% lower in the rhBMP-2 group (mean 117 
mL) than the autograft group (mean 353) (p = 0.0073). 
There was comparable improvement in SMFA scores 
between the two groups. No patient developed antibod-
ies to BMP-2 in the rhBMP-2/allograft group. Thus, 
Jones et al (2006) demonstrated that administration of the 
rhBMP-2/ACS combined with cancellous allograft for 
the treatment of diaphyseal tibial fractures with cortical 
defects was comparable with the overall clinical results 
achieved for patients who received autogenous bone Biologics: Targets & Therapy 2008:2(3) 352
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grafting. By eliminating autogenous bone graft harvesting, 
a rhBMP-2/allograft implant can provide signiﬁ  cant clini-
cal beneﬁ  t with decreased intraoperative blood loss and 
elimination of morbidity associated with autogenous bone 
graft harvesting. The authors concluded that rhBMP-2/
allograft is a clinically beneﬁ  cial and safe alternative to 
autogenous bone grafting in cases of tibial fractures with 
extensive tibial diaphyseal bone loss.
Table 2 Comparison of patient outcomes in control group and rhBMP-2 treatment group for the renamed nailing subgroup
Outcome criteria Control group (n = 48) rhBMP-2 group (n = 65) P value* Risk reduction (95% 
conﬁ  dence intervals)†
No. (%) of patients receiving 
bone graft
3 (6) 1 (2) 0.3100 67% (−201% to 96%)
No. (%) of patients receiving 
invasive secondary procedure‡
7 (15) 5 (8) 0.3549 47% (−64% to 83%)
Time to achievement of full 
weight-bearing§ (days)
84 ± 43 80 ± 37 NA NA
No. (%) of patients who had 
infection
13 (27) 12 (18) 0.3597 30% (−43% to 65%)
No. (%) of patients who had 
dynamization
10 (21) 11 (17) 0.6311 19% (−77% to 63%)
No. (%) of patients who had 
dynamization subsequent to 
screw breakage
2 (4) 3 (5) 1.0000 −25% (−594% to 77%)
Total no. (%) of patients who 
had dynamization
12 (25) 14 (22) 0.8251 12% (−74% to 55%)
Reproduced with permission from Swiontkowski MF, et al 2006. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data com-
bined from two prospective randomized studies. J Bone Joint Surg Am, 88:1258-65. Copyright © 2006. The Journal of Bone and Joint Surgery, Inc.
*Fisher exact test (two-tailed value).
†Relative risk reduction calculation = (1 − rate in rhBMP-2 group/rate in control group) × 100, as described by Bhandari et al.
‡Invasive secondary procedures were deﬁ  ned as one or more of the following: bone-grafting to treat delayed union or nonunion, ﬁ  bular osteotomy, and/or exchange nailing.
§The values are given as the mean and the standard deviation. NA = not available.
Table 1 Comparison of patient outcomes in the control group and rhBMP-2 treatment group for the Gustilo-Anderson Type-III open 
fracture subgroup
Outcome criteria Control group (n = 65) rhBMP-2 group (n = 66) P value* Risk reduction (95% 
conﬁ  dence intervals)†
No. (%) of patients receiving 
bone graft
13 (20) 1 (2) 0.0005 90% (41% to 98%)
No. (%) of patients receiving 
invasive secondary procedure‡
18 (28) 6 (9) 0.0065 68% (24% to 86%)
Time to achievement of full 
weight-bearing§ (days)
126 ± 61 95 ± 38 NA NA
No. (%) of patients who had 
infection
26 (40) 13 (21) 0.0234 48% (8% to 70%)
No. (%) of patients who had 
dynamization
14 (22) 14 (21) 1.0000 5% (–84% to 50%)
No. (%) of patients who had 
dynamization subsequent to 
screw breakage
16 (25) 7 (11) 0.0407 56% (1% to 80%)
Total no. (%) of patients who 
had dynamization
30 (46) 21 (32) 0.1085 30% (–8% to 55%)
Reproduced with permission from Swiontkowski MF, et al 2006. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data com-
bined from two prospective randomized studies. J Bone Joint Surg Am, 88:1258–65. Copyright © 2006. The Journal of Bone and Joint Surgery, Inc.
*Fisher exact test (two-tailed value).
†Relative risk reduction calculation = (1 − rate in rhBMP-2 group/rate in control group) × 100, as described by Bhandari et al.
‡Invasive secondary procedures were deﬁ  ned as one or more of the following: bone-grafting to treat delayed union or nonunion, ﬁ  bular osteotomy, and/or exchange nailing
§The values are given as the mean and the standard deviation. NA = not available.Biologics: Targets & Therapy 2008:2(3) 353
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Cost analysis
In a cost analysis study of the use of BMP-2 in open tibial 
fractures, Garrison et al estimated that the incremental 
cost per quality adjusted life-year (QALY) gained was 
greater than US$50,000 (Garrison et al 2007). There was a 
35% probability that cost per QALY gained was less than 
US$50,000. They concluded that the cost-effectiveness ratio 
is sensitive to the price of BMP and the severity of open tibial 
fractures. Jones et al (2004b) conducted an economic analysis 
to evaluate the cost of adding rhBMP-2 to the cost of initial 
fracture repair. In a comparison of treating an open tibial 
fracture with a nail versus a nail with rhBMP-2, they found 
that 10.5% of the rhBMP-2 cost would be offset by reductions 
in secondary interventions and infections. They estimated 
that the use of rhBMP-2 with intramedullary nailing would 
result in cost savings of US$3,570 per patient.
Conclusion
Marshall Urist’s discovery of BMP has been pivotal in 
understanding the biology of fracture healing and has 
been a source of intense clinical research as an adjunct to 
fracture treatment. Multiple in vitro and in vivo studies in 
animals have elucidated the complex biologic interactions 
between BMPs and cellular receptors and have convincingly 
demonstrated rhBMP-2 to be a safe, effective treatment 
option to enhance bone healing. Human clinical trials have 
provided further insight into BMP-2 dosage, time course, 
carriers, and efﬁ  cacy in fracture healing. Several human 
clinical trials have convincingly demonstrated the positive 
effects of BMP-2 on fracture healing in tibial defects. These 
promising results have provided hope that a new biologic 
ﬁ  eld of technology has emerged as a useful adjunct in 
the treatment of skeletal injuries and conditions. Further 
research and clinical studies are necessary to delineate the 
molecular mechanisms underlying bone formation and 
fracture healing.
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